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ABSTRACT
In the 1960's, psychedelic drugs were a part of not only popular culture, but also cutting-
edge psychology research. Scientists were studying these drugs in the hope of
understanding and treating various psychological and societal ills; but as psychedelics got
caught up in the counter-culture, they fell out of favor with the public, and practically
vanished from the research world as quickly as they'd appeared.
Now, decades after they all but disappeared, psychedelics are making a comeback.
Focusing primarily on research with psychedelics to treat post-traumatic stress disorder
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they're doing to explore the potential within these complex and controversial drugs.
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There was a time, not so long ago, when scientists were exploring the affordances of a
small group of compounds that, it was rumored, could cure everything from alcoholism
to obsessive-compulsive disorder; they could teach psychologists to see the world through
a schizophrenic's eyes, helping them better understand how to treat their patients; and,
to some, they held the promise of enlightenment, bringing the experience of ineffable
oneness to the masses and thus ushering in a new era of universal brotherhood.
They have been called psychomimetics, hallucinogens, and entheogens; but today most
people know them as psychedelics.
In the world of scientific research, the wheel of time can seem to turn unbearably slowly.
It may take years to build a telescope powerful enough to prove a theory that began as
one astronomer's thought experiment. A biologist may come up with a promising new
cancer treatment, only to see a decade or two roll by as the rigorous medical testing
process slogs on.
In both of those cases, the science continues forward, albeit more slowly than the
researchers would like. But what happens when your research-more, your entire field-
is frozen in its tracks for half a century?
You might ask Bill Richards that question. He began down the path of psychedelic
research almost fifty years ago. His field of endeavor, with all the promise it carried, rose
ever-upward toward the impossible heights of human imagination; but then as the work
he and his colleagues had been doing was carried away in the swell of a much larger shift
in the cultural tide, that meteoric rise rapidly became a precipitous free-fall. The doors of
public perception swung shut; the work stopped; Richards-like every researcher in his
field-was left...waiting.
But, slowly, the work is beginning anew Psychedelics, once the maligned manifestation of
the counter-culture, are beginning to resurface in medical research around the world.
Scientists are plumbing the long history of indigenous cultures' use of these unique
compounds, to better understand their healing possibilities.
As someone who worked hand-in-hand with the original psychedelic pioneers, and who is
central to the work going on now, Richards has a perspective on the long arc of
psychedelic history that few others share. When asked how he first got involved, he
laughs and says, "That's kind of a long story-but I do enjoy telling it..."'
At 23 years old, Richards was in grad school in Germany studying theology, but he'd heard
about some interesting research that was going on in the psychiatry department's clinic,
right behind his dormitory: Two friends of his had volunteered to be subjects in research
with a relatively unknown substance called psilocybin. One reported having a vision of
his father, who'd died in the war; the other said he saw images of SS officers marching
down the street. Richards was intrigued: He'd been studying his own dreams and
otherwise exploring avenues for personal growth; so he thought an experience with
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psilocybin might provide insight into his life-or maybe he'd have a hallucination. Having
never experienced one, he says he thought, "that sounded kinda neat."
So Richards volunteered. The screening process, if it could be called that, consisted of
being asked whether he "got drunk very often." While later psychedelic researchers
would consistently appeal to the paramount importance of "set and setting"-that is, the
mindset of the person undergoing the experience and the setting in which it takes place
-at that time there was no such thing. So Richards was taken down to the basement,
strapped to a gurney, given an injection, and left alone with his thoughts. "I drew on the
Methodist piety of my childhood," he said, and did his best to trust whatever came next.
In the kind of setup Richards was put in, psilocybin experiences can go terribly wrong:
It's easy for people to panic, or become paranoid; and under the influence of a bad
psychedelic experience, people in uncontrolled environments have even occasionally
gotten themselves killed.
So Richards' experience is a little surprising in that it went so -well.
"To my great amazement," he says, "[I} found myself entering into this very beautiful,
transcendental state of consciousness that I didn't even know was possible."
"Transcendence" is a word that often comes up when describing psychedelic experiences;
those who've used these substances often talk about losing their sense of individual
selfhood, or feeling themselves to be an integral part of something larger than themselves
-some even describe it as encountering God.
At one point a research assistant came in, wearing a white lab coat and a stethoscope, and
instructed Richards to sit on the edge of the bed so he could test his reflexes. The
researcher tapped at his knees, and Richards says he remembers feeling in that moment
"a great compassion for the infancy of science." It was suddenly clear to him that these
learned university researchers had absolutely no idea what they were doing. When it was
all over, Richards says he had two questions for the researchers: "What was that drug you
gave me, and how do you spell that?"
He was changed by his first encounter with psilocybin. "I became known as that
interesting American student who had the mystical experience," he says. He changed his
academic focus: Having gotten tired of 7am classes spent arguing over the precise
meaning of obscure Hebrew words, he switched focus to the psychology of religion-that
is, the study of the psychological mechanisms behind religious experiences, beliefs, and
behavior. During the '63-'64 school year he worked at the clinic guiding the sessions of
English-speaking volunteers who'd come to try psilocybin themselves. And meanwhile, he
says, he vaguely knew of work being done at Harvard by somebody by the name of Leary
Richards finished his Master's of Divinity at Yale, focusing on teaching and research in
religion, got a second master's in the psychology of religion at Andover Newton, and
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eventually earned a doctorate in clinical psychology ("I still can't wait to see what I'll be
when I grow up," he says cheerfully).
And while working toward his doctorate, Richards did something else. In the late 6o's
and early 70's he worked alongside psychedelic legends Stanislav Grof and Walter Pahnke
at the Maryland Psychiatric Research Center. What began as a one-off attempt to use
psychedelic therapy to help a coworker cope with illness grew into research on using LSD
to treat anxiety and depression in terminally ill patients. That work-the last real
psychedelic research Richards would do for decades-would ultimately become the
inspiration for some of the first work with psychedelics that's been done since it ran afoul
of public opinion in the previous century.
Today, Richards presents the figure of a bespectacled man with receding gray hair, and
large round glasses. When he speaks in front of an audience, once can imagine him
drawing from his divinity training-he rolls into a natural, easy-going cadence one might
expect to hear on a Sunday morning sermon. In private, he's the teacher and counselor,
philosopher and theologian. As he sits in his office chair surrounded by books new and
old on science, spirituality, and all points in between, he speaks in a slow and deliberate
meter, pausing between ideas in thoughtful silence.
Richards has been involved in psychedelics research longer than most in the field, giving
him a perspective few others can appreciate. But it must also have dealt him frustrations
that few others can comprehend: After his initial experience in Germany he took to the
research with gusto; but when the tide of public opinion turned against psychedelics, he
ended up the last U.S. researcher still working in the field. After publishing one final
paper on psychedelics in 1980, it would be twenty years before he'd be able to get back
into the fray.
In April of 1943, Swiss scientist Albert Hoffman synthesized a small sample of a
compound called lysergic acid diethylamide, or LSD for short. When he'd originally
stumbled upon it inadvertently, he'd dismissed it as having no obvious use-it wasn't clear
that it did anything. But in what he would later describe as a moment of intuition, one
day he felt instinctively that he ought to submit the compound to more thorough testing,
in case it had some useful properties he'd initially overlooked.
On that Friday in spring, Hoffman was forced to leave work early when he began feeling
restless and dizzy; and when he got home, he sank into a stupor he described as similar to
being drunk. Finding daylight unpleasant at the time, he closed his eyes and drifted into a
dreamlike state in which he experienced a play of shapes, colors, and images that ran
through his mind uninterrupted for about two hours.
Unable to come up with any other explanation for his bizarre experience, he decided
that, in spite of his usually meticulous laboratory manner, he must have inadvertently
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gotten a trace amount of the mystery compound on his skin. Wanting to know if it was
indeed this strange new chemical that had caused his Friday afternoon to take such an
unusual turn, he decided to take a risk: When he returned to work on Monday, he
deliberately ingested LSD.
At 4:20 that afternoon he mixed what he thought was a small sample of LSD in water
(about a quarter of a milligram), and drank it. At 5pm, he wrote in his journal:
Beginning dizzinessfeeling of anxiety, visual distortions, symptoms ofparalysis, desire to laugh.2
Those were the last words he could write that day, and even that was only through an
immense effort of will. His perceptions of reality were drastically altered, and he
struggled to speak, able only with great difficulty to communicate to his lab assistant that
he needed to go home.
At this point, the drug's effect on him had become severe enough to be frightening.
Objects in his surroundings took on grotesque shapes and seemed imbued with
malevolent life. His sense of his self-both his bodily awareness and his concept of will-
were disturbed as well. At times he thought he'd been possessed by a demon; later, he
wondered if he was dying, or perhaps had died already He lamented the thought of
leaving behind a wife and three young children, and despaired at the dark irony that his
work should be cut short by the very substance he'd discovered.
When he awoke the next morning, he felt no unpleasant after-effects, apart from still
feeling a bit tired. He wrote, "A sensation of well-being and renewed life flowed through
me. Breakfast tasted delicious and gave me extraordinary pleasure. When I later walked
out into the garden, in which the sun shone now after a spring rain, everything glistened
and sparkled in a fresh light. The world was as if newly created."
Never had he encountered any compound that could have such remarkable effects on
one's perception of the outer world and experience of the inner, and at a dose so low as to
be completely unprecedented. Hoffman knew then that this compound could be
immensely important to pharmacology, neuroscience, and especially psychiatry; but
looking back on the trajectory of what he would later call his "problem child," he
admitted that he had never imagined it would flourish beyond the confines of scientific
inquiry as a street drug. After his own experience with LSD had been so terrifying, he
couldn't believe anyone would want to ingest it on purpose.
In 1957, Life magazine published the story chronicling the experiences of a banker and
his wife as they tracked down rumored "sacred mushrooms" in Mexico used by locals that
reportedly granted mystical visions to those who ingested them-a ritual believed to be
at least two thousand years old.
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The magazine article signaled the first time that America in general became aware of
what would be commonly called "magic mushrooms" someday. But it also got Hoffman's
attention, who was curious whether the active ingredient in these hallucinogenic
mushrooms would turn out to be similar to his own LSD, or the mescaline derived from
the peyote cactus-the only other compounds he knew of that produced such
hallucinations. By 1958, Hoffman had isolated the chemical that provided the "magic" in
the magic mushrooms, and it became known as psilocybin.
Around the same time, a friendly competition began between psychiatrist Humphrey
Osmond and his friend Aldous Huxley (whom Osmond had given mescaline a few years
earlier) to try to find a word to describe the hallucinogenic experience. Several different
words were proposed, but it was Osmond who coined the term "psychedelic" from
Greek, meaning "mind-manifesting." It was, of course, this word that stuck.
Researchers all over the globe were anxious to get their hands on these compounds, and
Sandoz Laboratories-Hoffman's workplace-was happy to oblige. At first, no one was
quite sure what these drugs might befor One concept that got kicked around for a while
was the notion that these compounds functioned as "psychomimetics"-as drugs that
made mentally healthy people psychotic for relatively short periods of time (that is, a day
or so, rather than for life). It was hypothesized that, by using drugs that turned healthy
people crazy-for-a-day, clinicians could study disorders like schizophrenia in a more
controlled way. These drugs also were investigated for possible use in treating addictions,
particularly alcoholism-notably by the aforementioned Osmond, getting such work
enthusiastically endorsed by one of the founders of Alcoholics Anonymous. Scientists
were willing to try them out on everything and anything. In 1951, over one hundred
articles had been published in medical journals just on LSD. But by 1961, it was over a
thousand; and by the mid-6o's, it was already over two thousand. Psychedelic research
was catching like wildfire.
Ultimately, it was the notion that these compounds could open up previously obscured
regions of the mind for exploration that perhaps most inspired the collective imagination
of psychedelic researchers. But the re-imagining of these drugs as tools for self-
exploration and spiritual experience, though truer to their use in indigenous cultures,
ultimately was their undoing.
In the summer of 1960, three years after the magazine article on psilocybin had brought
hallucinogens firmly into public awareness, Timothy Leary was enjoying a vacation in
Mexico after his first year of being on the faculty at Harvard. He'd heard rumors before
of mystical Mexican mushrooms that granted visions, and recently a friend had shared
with him stories of his own experiences with these fantastical fungi. Apparently thinking
that sounded like just the thing to liven up his vacation, he made some inquiries, and
eventually was rewarded with enough mushrooms for him and a handful of friends to
experience their mystical powers firsthand.
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Leary's first experience with psilocybin had a profound and permanent effect on him. He
felt he'd learned more about the mind from one dose of psilocybin mushrooms than he
had in all his years of schooling and he believed, if nothing else, that this drug would
revolutionize the way psychology was done. As soon as he got back to Cambridge, he
started work on what would eventually be called the Harvard Psychedelic Project. By the
spring of 1961 Leary had given psychedelic drugs to at least 200 people-and he was just
getting started.
In 1962, Leary's doctoral student Walter Pahnke ran what would become one of
the most famous psychedelic studies in history, today usually called the Good Friday
Experiment. Pahnke, who was already a medical doctor and a minister, was curious
whether psilocybin could produce religious experiences, given the right people in the
right place.
And so, as the Reverend Howard Thurmond gave his Good Friday sermon, twenty
students and faculty from Harvard and Andover Newton Theological Seminary (where
Bill Richards got his degree in psychology of religion) were herded down into the
basement of Marsh Chapel and each handed a pill-half of them destined to take
psilocybin.
While the students who'd received a placebo were more or less quiet and orderly for the
length of the service, which was piped down to them via speakers, those who'd been
dosed with psilocybin were lying across the pews and on the floor, or wandering around
the room talking amongst themselves-or just to themselves-in awed whispers.
For many of those present who were given psilocybin, the experiment didprovide the
profound and spiritual experience Pahnke had intended. And, though Pahnke himself
wouldn't live to see it happen, dying in a scuba-diving accident only a few years later, his
experiment would one day play a vital role in resurrecting psychedelic research after
decades of dormancy
But While the Good Friday study would rise to the forefront of psychedelic history,
Leary was beginning to unravel. He was criticized for abandoning the strictly controlled
protocol that scientific inquiry demanded. Moreover, he'd gotten less and less careful
about who was getting drugs from him-including undergraduate students, against his
promises to the contrary to Harvard administrators. By 1963, all it took was an expose in
the Harvard Crimson, and Timothy Leary was booted out of Harvard.
But his ouster from Harvard only seemed to enflame him further; he'd already been
certain that the powers-that-be were not prepared for the psychedelic revolution he
envisioned-more, that they were actively fighting against it. Fed up and out of patience
with the research community and the establishment they represented, he took his
message of "turn on, tune in, drop out" to the youth and the counter-culture-the people
he saw as standing on the front lines of the coming cultural revolution.
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Instead of giving his wonder-drugs to academics to study, he meted them out to artists,
writers, and musicians: It was Leary who introduced the Beatles to LSD; without him,
there would have been no "Lucy in the Sky with Diamonds." In 1969 John Lennon
penned the song "Come Together" to be the anthem in Leary's bid for governor of
California against incumbent Ronald Reagan. Leary's gubernatorial bid was interrupted,
however, when in 1970 he was handed a twenty-year prison sentence for various drug
charges. In September of that same year Leary broke out of prison (with the help of some
friends) and fled the country. While Leary's time in the spotlight was far from over, he
had become too inflammatory for all but the most radical elements of the counter-
culture.
In many ways it was Leary's fierce devotion to psychedelics that ultimately destroyed
their legitimacy. By the late 6o's, psychedelics had become associated with agitators and
rabble-rousers-Leary chief among them. In a time of massive cultural upheaval,
psychedelic drugs were easy scapegoats to posit as the cause of the unrest in counter-
culture youth. Stories about psychedelics in the media painted them as dangerous: News
stories frequently gave airtime to the rumor that LSD caused chromosomal damage, (Bill
Richards mentions that he was part of a study conducted at the time that empirically
proved the rumor to be false, but it was completely ignored by the press), and an article
in the Journal ofthe American MedicalAssociation, warned that repeated psychedelic use
could cause "personality deterioration."
The thread continued to unwind. President Nixon labelled Leary "the most dangerous
man in America," and Leary wore it as a badge of honor, only further entrenching himself
and anyone and anything associated with him as rabidly anti-establishment. Sandoz got
increasingly shy about sending their synthesized drugs to researchers. LSD and psilocybin
had become illegal to possess in 1968, and after the passage of the Controlled Substance
Act in 1970 they were listed as Schedule I drugs, meaning they were deemed to be unsafe
and to have a high potential for abuse with no accepted medical use. In other words, no
one could have them or use them, for any reason. Within a decade, psychedelics
researchers went from publishing hundreds of studies a year to being unable to conduct
even one.
Bill Richards was one of the last to stop doing psychedelic research. He continued the
work he'd done with Grof and Pahnke, using LSD to help the dying work through their
anxiety and depression as the funding and the manpower for the research disappeared all
around him. Once the funds dried up completely, it would be decades before he'd be
involved in another psychedelic study
So, what happened? After all the "classic hallucinogens" (i.e., LSD, psilocybin, and
mescaline) were classified as Schedule I drugs, and both public opinion and research
funding turned completely away from psychedelics, how did they make a comeback? Brad
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Burge, one of the younger faces in the field today, says it's a complicated mix of several
components that came together at the right time.
Of course, he says, there's the simple matter of time: The so-called "acid panic" of the
6o's has eased out of the older generation's memory over the years, and the younger
generations don't know the first thing about it. That passage of time has lessened the
public's fear of hallucinogenic drugs, giving researchers an opportunity to proverbially
clear their names.
But, Burge adds, in a sense psychedelics never really went away. They never stopped being
street drugs, of course, but that's not what he means: When the scientific community was
publishing studies by the thousands on these compounds, making them illegal wasn't
going to be enough to stop people from being interested. Even though it became, as
Burge puts it, "professionally difficult,"3 psychedelic researchers continued their work by
taking it underground: When scientists could no longer conduct studies, they published
based on new analyses of the old data from before the purge (as Richards did, keeping
him putting out psychedelic studies for more than a decade after it became impossible to
acquire the drugs for research); they kept on writing, and (more importantly) they kept
talking-to each other, and to those factions of the public who would listen. That kept
the embers burning through the years. Then, an organizational shift at the Food and
Drug Administration (FDA) in 1992led to a change in the review process for these
studies: Research proposals were being analyzed based on their scientific rigor and merit,
rather than on the basis of which compound they were proposing to use. As Burge puts
it, they "committed} to science instead of politics."
This provided an opening, and researchers took it: By 1996, researcher Rick Strassman
published a study conducted at the University of New Mexico on the use of DMT
(dimethyltryptamine, the active ingredient in the complex hallucinogenic brew ayahuasca
that's used ceremonially by several indigenous cultures in South America, and also a
chemical produced in trace amounts in the body). It was the first psychedelic research
study using human subjects to be published in years. The doors were finally open again,
and little by little proposals began to trickle in from researchers interested in picking up
the thread of psychedelic studies.
Burge is part of the new generation taken an interest in the possibilities of psychedelic
medicine, himself not old enough to have been born until well after the first era of
psychedelic research already had ended; and when he talks, it's with a warmth and
hopefulness that are tempered with care and reason. He speaks like someone who
chooses his words with care; it's obvious he's enthusiastic about his work, but that he also
recognizes the patience it will take to see psychedelic medicine advance.
He's the Director of Communications for the Multidisciplinary Association for
Psychedelic Studies (MAPS), a non-profit organization that was founded in 1986 in
response to the criminalization of MDMA (3,4-methylenedioxy-N-methylamphetamine,
the active ingredient in the street drug commonly known as "ecstasy"). While the folks
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from the psychedelic studies group have their hands in a number of research projects
going on both in the U.S. and around the world, their main focus is a ten-year, ten-billion-
dollar plan to see MDMA become an approved drug for use in the treatment of post-
traumatic stress disorder (PTSD). MAPS is hoping to use MDMA as a "wedge" to open
the door to public acceptance of psychedelics for medical use, paving the way for other
drugs and other treatments to follow.
Burge says there are a few reasons why they're focusing on MDMA. For starters, having
appeared somewhat more recently on the public stage, it doesn't carry with it all the
baggage from the 6o's and 70's that the classic hallucinogens have to deal with-as he
says, it's just an "obscure acronym" to most. And of course, PTSD is a hot-button topic in
our culture now: the U.S. is becoming inundated with vets who suffer from stress disorder
and don't seem to respond to the already-available treatments. As Burge puts it, there's a
market here-preexisting therapies, including pharmaceutical interventions, haven't
entirely solved the problem, so they're "developing a treatment for a market that already
exists"-and MDMA could be a welcome addition in the fight against this debilitating
psychological condition.
But why this drug for this illness, in particular? Burge explains that ecstasy is sometimes
referred to as "the love drug": When researchers were first exploring its possible uses, it
was being utilized in couples' therapy The drug helps users to "open up," boosting their
trust and confidence in themselves and others. This makes it easier for patients to
develop a rapport with their therapist, and also helps PTSD sufferers confront those
traumatic memories that are the cause of their distress, rather than actively avoiding
them. The result, Burge says, is that you essentially get "years of therapy in a day"
MDMA acts on several areas of the brain to produce its effects. It decreases activity in
the amygdala, an area associated with fear and conditioned responses, while increasing
activity in the frontal cortex-associated with learning, memory, attention, and
emotional connections to people and events. But MDMA also stimulates the release of
oxytocin, a hormone that's gotten a lot of press lately due to its association with things
like falling in love, giving birth, and experiencing orgasm. Basically, it's an all-around feel-
good chemical.
And it appears to work. According to their research, 83% of their subjects-people whose
PTSD had failed to respond to other attempts at treatment-no longer qualified for a
PTSD diagnosis after going through MDMA-assisted therapy Further research has
shown those effects maintained for three and a half years.
People are starting to take notice. Burge says they might be looking at government
funding even before any major foundational support rolls in: Folks from high up the
chain of command have expressed interest in MAPS's work, and if they play the veterans
angle well enough they might even see some money come in from the Department of
Defense, though Burge says it's more likely they may see some funding from the National
Institutes of Health, or the National Institute of Mental Health.
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Roland Griffiths is a tall, thin man with gray-white hair and glasses. He's friendly and
soft-spoken, but speaks with a tone that conveys the easy authority of a man who has
long been an expert in his field. A respected full professor at Johns Hopkins with decades
of research under his belt on drugs and addiction, he's perhaps the world's leading expert
on caffeine. Many of his former students have gone on to hold important positions in the
drug research world, including as decision-makers at the National Institute on Drug
Abuse (NIDA). So when he first applied to the FDA for approval to do research with
psilocybin after the field had spent decades in stagnation, it probably didn't hurt that he
had essentially unimpeachable credentials. But why would an established and respected
pharmacologist at one of the premier research universities in the world risk straying from
the straight and narrow?
It started when Griffiths took up practicing meditation. He'd given it a try once years
earlier in grad school, but found it frustrating and abandoned it. But then about
seventeen years ago he tried it again in earnest, and his experiences in meditation got
him interested in spirituality and alternate states of consciousness-topics that, before,
had seemed unimportant to him. But his experiences on the cushion made him rethink
that. He shared his thoughts with friends and colleagues; and eventually, it was via friend-
of-a-friend introduction that Griffiths and Richards finally crossed paths.
Both had been living and doing research in the Baltimore area for decades, but it was
Griffiths' newfound interest in alternate states of consciousness that led them into each
other's circles. And the rest, as they say, is history.
Griffiths brought the expertise in experimental design and his decades spent establishing
himself in the Hopkins community, and Richards added his years of experience with
psychedelics as both a researcher and a clinician, having run hundreds of psychedelic
sessions. Their respective knowledge and insights complemented each other well, and so
they formed the core of what would soon become a dream team of researchers from
assorted backgrounds, eager and able to take on the challenge of researching one of the
world's most infamous drugs.
Psilocybin and LSD have a closely entwined pharmacology and history, and it was LSD
that Richards had used in his final studies before the collapse of psychedelic research; but
the Hopkins team chose to go with psilocybin for a number of reasons. First of all,
psilocybin in its naturally-occurring form has been used by indigenous cultures probably
for at least 2000 years. In addition, the effects of psilocybin wear off faster than they do
for LSD-psilocybin's influence at the doses they use typically lasts about 6 hours (8 or 9
at most), whereas the effects of LSD can persist for more than 12. Also, psilocybin
escaped the haze of the Leary era with less social stigma than its synthetic cousin:
Richards likes to say that most people can't even spell "psilocybin," let alone know much
about it. And finally, there is the issue that LSD may indeed carry more risks than
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psilocybin--a question currently still unclear. With the public perception hurdles the
researchers would have to overcome either way, Griffiths says, "We didn't need any
additional socially-perceived risk."4
Psilocybin was still a hard sell. But, to the team's surprise, it wasn't convincing the U.S.
government that was difficult-the FDA approval process went relatively smoothly, all
things considered; and they even received some funding from NIDA. But it took a great
deal of convincing before the university approved their research.
But that's not really surprising: Johns Hopkins is a top-tier university, renowned for the
caliber of its research, especially in the medical field; and perhaps, if a spotless reputation
is the most easily tarnished, then the university's administration had every reason to be
wary of becoming known as the school that resurrected the psychedelic ghosts of yore.
The process of getting approval from the various ethics and funding committees at the
university was gruelingly thorough. It took two separate institutional review boards, and
then, the Hopkins legal team wanted to take a crack at the protocol. Still, Griffiths doesn't
hesitate to say that he's proud of the folks at Hopkins who carefully scrutinized their
proposed research-both for being extremely cautious and careful in considering the
information they were given, and in ultimately deciding that the benefits of the research
outweighed any possible risks. By 2000, the pharmacy at the school was producing
psilocybin, and Griffiths and his team could start recruiting volunteers for a pilot study.
They had to be incredibly careful in screening their participants: Any study involving
human subjects is bound to be deeply scrutinized, and that goes double when researchers
are working with a compound that's got a bad reputation working against it. So the team
wanted only healthy volunteers with no previous experience with psilocybin-or any
other hallucinogen, for that matter.
Taking prescription medications that might interact with psilocybin automatically ruled a
person out, as did certain psychological disorders-even a person who presented no
mental illness herself, but who had a history in her family, could be disqualified. This
close to bringing psychedelic research back from the dead, the last thing the Hopkins
crew needed was a research participant suffering a psychotic break and having a
meltdown in their lab.
The Johns Hopkins team also took to heart the lesson learned by their predecessors on
the importance of "set and setting." Before the first generation of psychedelic studies was
shut down, researchers had learned that a person's mindset going into a psychedelic
experience and their environment-where they were and who was there with them-had
a huge effect on how that experience went. No more strapping unwary grad students to a
gurney and abandoning them in a basement; participants in the Hopkins studies were
thoroughly briefed on what they might experience under the influence of psilocybin,
given plenty of time to get to know the two guides who would talk them through the
experience, and when the time came they spent the day in a comfy room with couches,
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books, and soothing music to listen to, their guides ready and waiting if they needed
anything, even if it was just a reassuring hand on the shoulder.
Taking their inspiration from Pahnke's Good Friday Experiment, the Hopkins team
wanted to explore whether psilocybin could be used to to elicit meaningful, mystical-type
experiences. While they specifically sought out volunteers who had active spiritual lives,
they defined the term very broadly: While Richards recalls at least two clergy who took
part in the study, being seriously dedicated to a hatha yoga practice could be enough to
get the check in the block.
It took them six years to get 36 subjects through the study; but in the end, the results
were worth it. Participants did, indeed, have mystical experiences that they deemed
profoundly meaningful: Two months after the fact, more than half the participants
queried said it was among the top five most meaningful experiences of their lives-on par
with their wedding day, or the birth of a child. A follow-up study more than a year later
found that more than half of the participants still considered their psilocybin encounter
one of the most personally andspiritually meaningful experiences of their lives;
furthermore, measures that had been taken shortly after the study-affect, quality of life,
and spirituality-that showed elevation after the psilocybin experience remained elevated
more than a year after the fact. An additional follow-up study showed that many
participants showed increases in a personality measure called Openness to Experience.
Part of the "Big Five," one of the most commonly used personality measures in
psychology, Openness concerns things like imagination, favorable response to variety, and
intellectual curiosity. That finding was particularly important, as it contradicted a large
body of evidence in psychology research suggesting that personality traits in adults are
essentially fixed. Not only did the Hopkins group find that psilocybin could occasion a
change in personality, but that the change was persistent-maybe even permanent.
The results of their research were heartening, as was the public response: Far from the
fear-mongering and hysteria of the first psychedelic era, the media reported their work in
mostly calm and straightforward terms, avoiding the sensationalism the Hopkins team
knew was possible.
For their next project they took their inspiration from Richards' work at the tail-end of
the earlier psychedelic research, and sought to continue the studies with cancer patients
where they had left off decades before. And at that point the idea had caught on with
other researchers as well: Researcher Charles Grob at UCLA did a small pilot study with
io participants that was published in201o, and researchers at NYU are also currently
running a study with cancer patients that closely mirrors the work being done at
Hopkins.
And while that's going on, the Hopkins group is branching out: They're currently
studying how psilocybin might assist people pursuing a spiritual practice (meditation, in
this case), as well as looking into using psilocybin to help people quit smoking-again, an
offshoot of the addiction research that was being done decades ago.
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When it comes to research yet to be done, Griffiths says, "We just haven't scratched the
surface."5 He rattles off a dozen different directions he says the research could-and
should-take: The actual neurophysiology of psilocybin needs to be studied much more
fully; individual differences between people in their susceptibility to psilocybin in general,
and psilocybin-induced mystical experiences specifically, should be examined; the
importance of "set and setting" should be rigorously studied in a controlled way; and so
on. And, of course, the possible therapeutic applications of psilocybin--its use in treating
anxiety and depression, addiction, obsessive-compulsive disorder, and cluster headaches
all are being researched at the moment-still need to be studied further.
Already, psilocybin research has gotten easier. Anthony Bossis, one of the researchers on
the NYU team, says that their own studies were green-lighted through the approval
process unbelievable quickly and easily, taking less than a year-and he believes that's
largely thanks to the Hopkins team's having set a precedent for safe, scientifically
rigorous research.
Griffiths says he's encountered some skepticism in the professional community, but
maybe not for the reasons one would think. There are definitely some who question
whether using psychedelics is worth the risk: They urge caution both because the risk of
psychosis, though minimized in the Hopkins research, is still very real, and because the
last thing the world needs is a repeat of the psychedelics mess of the 6o's. But it's more
the spiritual element of the research that's getting mixed reviews.
Although the psychology of religion is a well-established field of study, to those
unfamiliar with it Griffiths says he can imagine it must sound flaky to start talking about
volunteers' experiences of "the interconnectedness of all things." And there are, of
course, limitations when studying people's subjective experiences. But, he counters, the
effects they're seeing in the research are "dose-dependent, predictable, [and} replicable."
There's definitely something going on here, and it's worth studying.
On the other hand, Griffiths says, you also get some who are offended by the research on
spiritual grounds: As people did in the 6o's, some object to the notion of "God in a
pill" (a phrase Griffiths stresses he would never use), deeming the psychedelic experience
to be false or misleading. Among those who value mystic experiences, there are some who
seem to feel that triggering them in a laboratory setting in some way demeans the
experience. Or, they view this research as a "systematic dissection" (Griffiths' words) of
religious experience, and believe this is a case of materialism encroaching on religion.
And then, of course, Griffiths says a little derisively that you encounter the One-True-
Religion types who say that a religious experience had through Christian centering
prayer, for example, is valid, but those had by any other means are not.
As for what should happen to psychedelics in the future, opinions are a little mixed-
though all seem to agree that a cultural sea-change is necessary if psychedelics are to gain
a legitimate role in our society At the very least, there seems to be agreement that
psilocybin has no business being a Schedule I controlled substance; despite the risks
associated with it (and the researchers readily concede that psilocybin can., be dangerous),
they would like to see its potential for important medical use recognized, as well as the
fact that it is non-addictive (a point NIDA already concedes).
The folks at MAPS are maintaining their focus on MDMA right now, and Burge believes
that alone will keep them busy for the next twenty years. There has never been a drug
taken off the Schedule I list and reclassified as safe for medical use; if MAPS succeeds, it
will be a first. But Burge stresses that, at heart, they're getting at a much larger issue
concerning our culture's relationship to pharmaceutical drugs.
The dominant paradigm at the moment is that psychological disorders are treated with a
drug that a person takes basically for the rest of his life. As Burge puts it, the current
pharmaceutical-centered school of thought says "There's a hole in your brain that we
have to fill with this drug."6 But treatment like the kind MAPS is exploring using
MDMA uses very few doses of a drug-sometimes just a single use-and the emphasis is
on using the drug as a catalyst to allow patients to work their way through their own
healing. If this new paradigm is adopted, Burge says, it will "radically change the entire
medical field." Richards makes a similar point, frequently describing psychedelics as the
"catalyst" that allows transformation and healing to occur-a term many other
psychedelic researchers like to use as well. As Burge frames it, rather than using
psychedelics as a sort of cure for our psychological ills, they provide an altered worldview
that helps us to "accomplish that healing ourselves."
As for the Hopkins work, Griffiths says he's not particularly married to psilocybin, per se:
What matters to him is that the experiences psilocybin induces have an apparently
meaningful, healing effect. So, to him, the drugs are a means to an end. But because there
are plenty of examples of people having these mystical experiences -witbout, drugs-
instead using methods like meditation-he's very open to the possibility of exploring
other tools for getting people into that state. If it's even safer than psilocybin and
similarly reliable, he's all for it.
Indeed, in some cases that seems to be the best way to go forward: When a group of
researchers at Harvard looked at cases of people self-medicating with psilocybin or LSD
to treat cluster headaches-sometimes called "suicide headaches" because they are
extraordinarily painful and long-lasting-they found that these drugs worked amazingly
well. So one of the researchers, John Halpern, went on to found a company that's now
experimenting with treating cluster headaches using a compound that's chemically
similar to LSD, but without any hallucinogenic effects.
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Perhaps because of his unique experiences with the ups-and-downs of the field, Richards
is both cautious and optimistic. Like Burge, he recognizes that, in using psychedelics to
treat psychological illness, a larger cultural issue is at stake: Whereas a depressed person
can be put on Prozac for the rest of her natural life (and that's considered socially
acceptable), psilocybin treatment might use one, maybe two doses in a lifetime-not a
good business model for the drug companies. So he has difficulty imagining too much
enthusiasm for psychedelics coming from that area (although Burge doesn't think that
matters quite so much; he feels that there's an economic niche that's been left empty
thus far, and psychedelics could fill it).
We also have an entrenched "tradition'7 (as Richards calls it) in our culture of proscribing
tranquilizers and anti-depressants to people diagnosed with a serious illness just as a
matter of course-and those drugs don't play well with psilocybin. So there is the issue
that what's socially acceptable at the moment also happens to be what makes
pharmaceutical companies a lot of money, and Richards recognizes the difficulty inherent
in trying to change that.
Still, he has high hopes. Richards would like to see psilocybin become, for lack of a better
word, a sacrament. Like peyote and ayahuasca, he sees a role for this classic psychedelic
in initiating people into mystical, transcendent experiences-something he believes we
need much more of in our society. In particular, he says it's a "personal dream" of his to
see psilocybin used in seminaries as an optional (but encouraged) rite of passage, of sorts,
to give burgeoning spiritual leaders a Moses-on-the-Mountaintop moment that they can
then carry with them as they go into ministry, a mystic wellspring that they can draw
from in their lives as spiritual mentors.
But the niche that Richards envisions psilocybin filling in the distant future gets at what
he sees as a much larger cultural blind-spot.
The Hopkins team had some difficulty finding volunteers when they began their
psilocybin studies-not something really surprising, Griffiths points out; after all, they
-were- asking people if they'd like to spend a day in a laboratory taking hallucinogens in
the name of science. How many sane, healthy people would raise their hands for
something like that? Then, when they started the cancer study, volunteer numbers took
an even deeper and completely unexpected nose-dive. The question was, why?
The researchers from the various psilocybin groups offer a number of possible
explanations. Oncologists often get to see their patients for only a few minutes at a time
as it is; so how much of that precious time can they be expected to spend trying to
explain the nuances of some research study looking for new recruits? In a similar vein, so
many cancer patients have been in and out of countless laboratories promising the latest
and greatest treatment option; and so the last thing they want to hear is that a herd of
lab-coat-wearing, clipboard-toting scientists wants them to sign up to be guinea pigs in
yet another study. And of course, there's also the issue that participants are being asked
to spend time in a research study that is not, offering any chance of a cure; instead, it's at
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best offering them what must sound terribly morbid and hopelessly hollow: as Bossis
from NYU puts it, "a good death."8
All the researchers seem to agree that this touches on a much larger issue than
psilocybin: We as a society have an unhealthy relationship with our own mortality.
Pondering the issue, Griffiths says, "We have a very disordered relationship in our culture
toward death and dying, don't we?"9 By and large, he points out, we respond to death
with fear and denial-and the medical establishment hasn't helped much. He concedes
that it has gotten better in recent years, but palliative care has a long way to go. And so,
while Griffiths certainly doesn't foresee (or want) psilocybin to show up at the corner
pharmacy someday, he would like to see it approved for use in a therapeutic setting,
especially for end-of-life care. But whether a larger cultural shift would need to take place
beforehand, he finds it hard to say.
Bossis, who was an undergrad just as the first era of psychedelic research was shutting
down, nonetheless was immediately intrigued by what he was reading. Unable to pursue
psychedelic research after he finished college, he went into grad school for clinical
psychology, ultimately earning his doctorate. He's a specialist in psychosomatic illness,
the psychology of pain, and palliative care, and is also interested in consciousness,
comparative spirituality, and mysticism. In other words, the current resurgence of
psilocybin research is right up his alley. He agrees that our culture's denial of "end of life
[as] a part of life" is a huge problem, and one that will go hand-in-hand with the future
acceptance of psilocybin as a tool for treating what he calls "psycho-spiritual health." l0
This sort of thing is precisely the reason Burge thinks MAPS's work with MDMA is
easier to sell to the public than the sort of work the Hopkins folks are doing. PTSD is a
known entity in our culture: The public has a fairly concrete grasp on what it is, and
understands the need to find effective treatments. Similarly, the effects of MDMA are
fairly easy to describe in a way that a person with no experience with the drug can
understand: It makes you feel happy and calm, makes it easier to be open with others;
MDMA users describe it as feeling more like themselves than usual. That's something a
person can wrap their heads around.
But with psilocybin or LSD, people talk in terms of "self-transcendence," or "cosmic
oneness"-words that would smell like patchouli and sandalwood if they had an aroma,
and that to most people scream "New Age hippie B.S." Which makes the task of gaining
public approval a bit more difficult.
Still, even the most circumspect of the researchers working with psilocybin sound like
true believers when they talk about their work. Even if it is difficult to put into words
exactly bow these mystical experiences help people, they're quite certain that they do-
and the people who've participated in the studies say so themselves, which seems to back
the researchers up.
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Richards calls it "profoundly meaningful work"n-both in the past and the present. He
says it's a uniquely meaningful experience working with the dying, particularly since we
live in a culture inundated with the denial of death. He says the terminally ill often find
themselves surrounded by doctors, family, and friends who all insist that everything's
going to get better, and he says for patients faced with that scenario, "the world starts to
feel bizarre."
He tells the story of a woman who'd been in the LSD study back in the 70's: One day
while she was being treated in the hospital, she was in the bathroom when she heard her
surgeon talking to residents outside-and that was how she found out that she had
terminal cancer. Afterward, Richards says, she wondered whether she should tell her
doctor that she knew; she worried whether he,, could handle it.
"I've learned that most people are much more resilient than we give them credit for,"
Richards says. In the LSD study, and so far in the current research at Hopkins, he's found
that psychedelic experiences often have a profoundly positive impact on patients-and,
more importantly, on the people around them.
When the dying come to terms with death, they become more open and willing to talk
about what really matters to them, what they want out of the life they have left. That can
be enormously important to their families-"and beautiful things happen," says Richards.
He's also seen patients become more involved in their treatment after their psychedelic
experiences, taking more responsibility for deciding what they want-even telling their
surgeons off when they need to.
Many patients, Richards says, were labelled as bedridden; but they were confined to bed
not by their physical illness, as it turned out, but by depression. One such patient,
Richards said, after undergoing psychedelic-assisted therapy, "literally..got out of bed and
danced at her daughter's wedding."
Terminally ill patients who underwent this kind of therapy reported decreased anxiety
and depression, less fixation on pain, and greater intimacy in their interactions with other
people.
"It really helps people live the time that's left," Richards says. Psychedelics can't cure
cancer, but that's not the point: Richards says there is "so much unresolved grief" in our
culture because we live in denial of our own mortality; the aim of psychedelic-assisted
therapy is to give people a mental space in which they can work through the fear and
anxiety associated with death, so they can more fully enjoy the life they still have ahead
of them.
"The human organism is capable of coming to terms with death in a meaningful way," he
says. "We don't have to protect people from it."
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Writing about the work they did together during the first wave of psychedelic research,
Stanislav Grof wrote:
One aspect of this work will necessarily elude even the most sophisticated methodology in all similar
studies conducted in the future. It is the depth of the personal experience of those who are privileged
to share the situation of dying with another human being and see the psychological crisis so frequently
accompanying the encounter with death alleviated or even completely reversed as a result of a
psychedelic experience. Repeatedparticipation in this special event is more convincing than numerical
data, and leaves no doubt in the mind of the psychedelic therapist that this work with the dying is
-orthpursuing.2
For now, the psilocybin researchers are forced to be patient. The Hopkins cancer study,
running since 2007, so far has run half the number of subjects they're aiming for; and the
NYU team, which started running subjects in 2009, has reached a little over a third of
their own goal. So things are progressing, albeit slowly. As they continue to remove
themselves further and further from the specter of Timothy Leary and the "acid panic"
he induced, they know that any great cultural revolution will be a long time coming. For
now, Richards says with a sagely smile, "All we can do is what we can do today."3 But
really, that they're doing anything is itself an impressive feat.
Richards' office is at the back of his home, nestled in a hilly, wooded suburb outside
Baltimore. His office windows overlook an expansive and meticulously manicured
backyard reminiscent of ajapanese garden, with carefully cared-for greenery, gently
curving walkways, and a well-stocked bird-feeder. The space matches the personality of
its quiet, contemplative owner, who smiles easily, speaks softly, and laughs often.
"As you can imagine, for me especially," he says, "it's a real joy to be part of the rebirth of
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